Living with sarcoma: Chinese innovation addresses TGCT patients' needs

As the global medical community marks International Sarcoma Awareness Month this July, attention is turning to tenosynovial giant cell tumors — a rare, locally aggressive neoplasm progressively destroying joint function and severely impairing patients' quality of life. Experts say Chinese therapy is reshaping the TGCT treatment landscape and redefining its future.

For decades, TGCT has posed a major clinical challenge worldwide, plagued by limited therapeutic options and persistently high recurrence rates.

TGCT is classified into two main subtypes, with the diffuse form presenting a substantially greater challenge. Whereas localized TGCT remains relatively confined, the diffuse variant aggressively penetrates joint spaces and surrounding anatomical structures. As a result, radical surgical resection is rarely attainable and the risk of local recurrence remains persistently high.

"Resection frequently induces irreversible structural injury to critical joint components and clinical data indicate that 34 percent to 72 percent of patients develop radiographically confirmed recurrence, necessitating repeated surgical interventions," Doctor Liu Weifeng, from Beijing Jishuitan Hospital (National Center for Orthopedics), said of the inherent limitations of conventional surgical management in TGCT.

Historically, the absence of disease-modifying systemic therapies has confined treatment options for patients with diffuse or recurrent TGCT almost exclusively to surgery — a modality associated with cumulative functional impairment and well-documented long-term morbidity.

This therapeutic landscape, however, has begun to evolve with the advent of CSF-1R-targeted therapies spearheaded by pimicotinib — a novel therapy originating from China. In December 2025, China granted approval to pimicotinib for the treatment of adult patients with symptomatic TGCT for which surgical resection will potentially cause functional limitation or relatively severe morbidity — a landmark regulatory decision representing the first disease-modifying systemic therapy approved for TGCT in China.

Robust clinical evidence supporting this therapeutic approach was established in the global, randomized, double-blind Phase III MANEUVER trial, the results of which were published in The Lancet in March 2026. More recently, in June 2026, pimicotinib secured marketing authorization approval in Canada, which reinforced its growing international recognition as a standard-of-care option.

Doctor Min Li from West China Hospital, one of the country's largest centers for TGCT management, explained that CSF-1R inhibitors exert therapeutic effects via a highly selective blockade of the CSF-1R signaling pathway, delivering a precision treatment modality unattainable by surgery alone.

"We have observed promising therapeutic responses among treated patients. Many reported substantial pain relief alongside improved joint mobility and daily functioning — outcomes that could never be achieved through surgery alone," Min said. This targeted therapy now serves as a foundational component of integrated, multimodal management — marking a paradigm shift from surgical intervention toward longitudinal, patient-centered chronic disease control.

Beyond tumor control, patient-centered outcomes have emerged as fundamental endpoints in contemporary TGCT treatment framework. "What defines therapeutic success for patients is not merely radiographic response, but whether they can regain self-sufficiency in daily activities, return to employment, and reengage meaningfully with their personal and social environments," Doctor Yang Qingcheng from Shanghai Sixth People's Hospital (National Center for Orthopedics) said. "By preserving synovial-joint homeostasis and mitigating structural degradation, CSF-1R inhibition enables durable functional recovery — resolving the longstanding clinical dilemma wherein effective local tumor control historically necessitated irreversible sacrifice of joint function".

This year's International Sarcoma Awareness Month, themed "Living With Sarcoma: Life Goes On", focuses on the real-life struggles of rare tumor patients, including those with TGCT. Beyond raising awareness, the campaign highlighted persistent unmet needs while celebrating groundbreaking advances emerging worldwide. By championing integrated, patient-centered chronic care, the initiative aims to help more patients preserve joint function, restore mobility, and reclaim their quality of life — and calls for a collective global effort to deliver more hopeful, accessible care for every sarcoma patient.

Please contact the writer at hanjingyan@chinadaily.com.cn